Jiamine Mycin Injection Wins National Category II New Veterinary Drug Approval

On May 7th, the Ministry of Agriculture and Rural Affairs issued the 296th announcement, approving "Jiamine Mycin Injection," jointly developed by the Animal Health Products Factory of Guangdong Wens' Dahuanong Biotechnology Co., Ltd. and other units, as a Category II new veterinary drug. This marks the 7th Category II new veterinary drug approved for Dahuanong's Animal Health Products Factory, signifying a major breakthrough in the company's innovation in the field of new veterinary drugs.

It is reported that Jiamine Mycin is a new type of macrolide antibiotic specifically for animals, which has a strong bactericidal activity against pathogenic microorganisms such as Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Mycoplasma that cause respiratory diseases in pigs and cattle. Jiamine Mycin injection has the advantages of being safe and efficient, having a broad antimicrobial spectrum with strong activity, being rapidly absorbed in the body, concentrating in lung tissue, and providing full-course treatment with a single dose. It has been widely used in countries such as the European Union, the United States, and Canada, and has achieved good therapeutic effects in the prevention and treatment of respiratory diseases in pigs and cattle. The successful development of Jiamine Mycin injection will provide new technical support and solutions for the prevention and control of animal respiratory diseases, meet the medication needs of clinical breeding, and safeguard the healthy development of China's breeding industry.

By / Liang Jingkang, Emerging Chemicals Branch of Dahuanong Business Division.